Catalyst Pharmaceuticals stock rises 6.94% to new 52-week high

11 articles · Updated · MarketWatch · Apr 27

Shares closed at $29.27 on Monday, surpassing the previous high of $28.10 set on April 24, with trading volume reaching 9.3 million.
Catalyst Pharmaceuticals outperformed major competitors such as Johnson & Johnson and Pfizer, as the NASDAQ gained 0.20% while the Dow Jones slipped 0.13%.
The stock’s trading volume far exceeded its 50-day average of 1.3 million, highlighting increased investor interest during a mixed session for the broader market.

Is Catalyst Pharma truly worth double its record-high stock price, as some valuation models suggest?

What does the intense buyout interest in Catalyst signal for the future of M&A in the rare disease drug market?

If the takeover deal collapses, does Catalyst's pipeline have enough strength to sustain its momentum?

Is the rumored Angelini Pharma takeover of Catalyst a real possibility or just speculative market hype?

Could a foreign takeover jeopardize the future of Catalyst's drug development for American patients?

How will President Trump's new pharma tariffs influence foreign acquisitions of American biotech companies?